Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Priothera SAS logo — Adding Quality Years of Life

Priothera SAS

Adding Quality Years of Life

Founded 2020 France France 21 employees Debt Financing Total: $49.00M Biotechnology, Health Care +1

General Information

Company Name Priothera SAS
Founded Year 2020
Location France France
Founders / Decision Makers
Team member
Employees 21
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Debt Financing
Social

BounceWatch is an independent company data service, not affiliated with Priothera SAS. To contact Priothera SAS, visit priothera.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Priothera SAS compare?

A PDF of Priothera SAS and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Priothera SAS soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Priothera SAS

Priothera is a France-based biotechnology startup founded in 2020, with a focus on improving the lives of patients suffering from hematological malignancies. The company's dedication is evident from its slogan, "Adding Quality Years of Life," and its innovative approach. Priothera's main aim is to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) by delivering an innovative immune modulator.

In April 2022, the company secured a significant €1.50M Debt Financing investment, with the support of Bpifrance. This injection of capital not only showcases the confidence that investors have in the company's mission but also provides Priothera with the resources necessary to further develop and advance its groundbreaking approach.

As a startup operating in the fields of biotechnology, healthcare, and pharmaceuticals, Priothera is positioned within highly impactful industries. With its innovative solution addressing a pressing medical need, the company has the potential to make a significant difference in the lives of patients. The recent investment represents a crucial stepping stone in Priothera's journey to revolutionize treatment options for hematological malignancies.

Business keywords: hematological malignancies, immune modulator, allogeneic Hematopoietic Stem Cell Transplantation, clinical-stage company, sphingosine 1 phosphate (S1P) receptor modulators

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing €1.50M 1
Bpifrance
Bpifrance
04 Apr 2022
Debt Financing €17.50M 1
European Investment Bank
23 Feb 2022
Series A €30.00M 4
Earlybird HealthCap Fountain Healthcare Partners
Earlybird, HealthCap +2
12 Oct 2020

Latest News

View All
Earlybird Health promotes two new partners as firm deepens biotech and analytics focus — Tech
Earlybird Health promotes two new partners as firm deepens biotech and analytics focus
Tech Oct 29, 2025
Earlybird Health closes twice-larger second fund, will write bigger checks — Techcrunch
Earlybird Health closes twice-larger second fund, will write bigger checks
Techcrunch Feb 14, 2024
Earlybird Health closes €173 million fund to focus on healthcare innovations that improve patient ou... — Eu-startups
Earlybird Health closes €173 million fund to focus on healthcare innovations that improve patient outcomes
Eu-startups Feb 14, 2024

Priothera SAS Alternatives & Competitors

View All Alternatives
Priothera SAS vs
Connect Biopharma
Connect Biopharma United States

Global Clinical Stage Company Connecting Patients with Innovation for Life

Series C
30 employees
Biotechnology, Health Care
Priothera SAS vs
GammaDelta Therapeutics
GammaDelta Therapeutics United Kingdom

GammaDelta Therapeutics focuses on using γδ T cells to improve survival rates of patients with cance...

Seed
4 employees
Biotechnology, Health Care
Priothera SAS vs
ONK Therapeutics
ONK Therapeutics Ireland

Pioneering optimally engineered NK cell therapies to cure patients with cancer.

Series A
20 employees
Biotechnology, Health Care
View all alternatives

FAQ About Priothera SAS

Adding Quality Years of Life
Priothera SAS was founded in 2020.
Priothera SAS is headquartered in France.
Priothera SAS operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on hematological malignancies, immune modulator, allogeneic Hematopoietic Stem Cell Transplantation and clinical-stage company.
Priothera SAS has approximately 21 employees.
Priothera SAS has completed 3 funding rounds, raising a total of $49.00M. The latest funding stage is Debt Financing.
Top alternatives and competitors to Priothera SAS include Connect Biopharma, GammaDelta Therapeutics, ONK Therapeutics, Caribou Biosciences, Harpoon Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Priothera SAS and Connect Biopharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Priothera SAS, https://bouncewatch.com/company/priothera, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes